Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A randomized study of alpha-interferon plus ribavirin for 6 months or 12 months for the treatment of chronic hepatitis C in patients with bleeding disorders.

Haemophilia : the official journal of the World Federation of Hemophilia - 1 Mar 2002

Schulman S, Kinnman N, Lindmarker P, von Sydow M

Abstract excerpt

Little is known about the optimal treatment in patients with chronic hepatitis C virus (HCV) who were infected by pooled plasma products. The aim of our study was to compare the efficacy of 6 and 12 months of combination therapy with interferon alpha-2b and ribavirin in patients with bleeding disorders and chronic HCV. In a randomized open study, 61 patients with haemophilia or von Willebrand disease received...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Blood Coagulation Disorders

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Administration Schedule

Share to Drug Therapy, Combination

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Ribavirin

Source

Identifiers

PMID: 11952848
DOI: 10.1046/j.1365-2516.2002.00629.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A randomized study of alpha-interferon plus ribavirin for 6 months or 12 months for the treatment of chronic hepatitis C in patients with bleeding disorders.PMID 11952848Read ↗

Treatment of chronic hepatitis C in haemophilic patients with interferon and ribavirin: a meta-analysis.Semantic proximity Read ↗

Treatment of chronic hepatitis C virus infection among Brazilian haemophiliacs.Semantic proximity Read ↗

Haematological support during peg-interferon therapy for HCV-infected haemophiliacs improves virological outcomes.Semantic proximity Read ↗

Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months.Semantic proximity Read ↗

Treatment of chronic hepatitis C: our experience.Semantic proximity Read ↗

What is the safe duration of therapy for patients infected with HCV genotype 6?Semantic proximity Read ↗

Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha. Multicenter Interferon Beta Italian Group Investigators.Semantic proximity Read ↗

"12 weeks' stopping rule" in the treatment of genotype 1 chronic hepatitis C: two prognostic categories under the same label?Semantic proximity Read ↗

Clinical spectrum of hepatitis C-related liver disease and response to treatment with interferon and ribavirin in haemophilia or von Willebrand disease.Semantic proximity Read ↗

Interferon and ribavirin in HIV-negative haemophiliacs with chronic hepatitis C who were nonresponders to a previous interferon treatment.Semantic proximity Read ↗

Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial.Semantic proximity Read ↗

[Treatment of chronic hepatitis C with PEG-interferon alpha-2b and ribavirin: 24 weeks of therapy are sufficient for HCV genotype 2 and 3].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.